Revalesio, a clinical-stage pharmaceutical company focused on neurological disorders, announced on Wednesday results from its Phase 2 RESCUE clinical trial, showing that ischemic stroke patients treated with 1.0 mL/kg/h RNS60 plus standard of care endovascular thrombectomy (EVT) within 12 hours of stroke onset showed increased benefit compared to placebo than those being treated within 24 hours.

Approximately 75% of trial participants experienced a reduction in infarct volume growth (brain tissue loss) post-EVT of more than 50% (nominal p